NZ226005A - Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof - Google Patents
Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereofInfo
- Publication number
- NZ226005A NZ226005A NZ226005A NZ22600588A NZ226005A NZ 226005 A NZ226005 A NZ 226005A NZ 226005 A NZ226005 A NZ 226005A NZ 22600588 A NZ22600588 A NZ 22600588A NZ 226005 A NZ226005 A NZ 226005A
- Authority
- NZ
- New Zealand
- Prior art keywords
- human
- cytokine
- manufacture
- processes
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The conjugates consist of a cytokine, for example interferon alpha, and human immunoglobulin, if required linked via an organic bridge and are used in pharmaceutical preparations for the treatment of viral infections and tumours. Compared with the free cytokine, the conjugates have a longer residence time in the plasma and tissue and thus improve the therapeutic effect.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH335787 | 1987-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ226005A true NZ226005A (en) | 1990-10-26 |
Family
ID=4254228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ226005A NZ226005A (en) | 1987-09-02 | 1988-08-31 | Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0305967B1 (en) |
JP (1) | JPS6490200A (en) |
KR (1) | KR890005137A (en) |
AT (1) | ATE88900T1 (en) |
AU (1) | AU627694B2 (en) |
DE (1) | DE3880766D1 (en) |
DK (1) | DK486588A (en) |
ES (1) | ES2054753T3 (en) |
FI (1) | FI884013A (en) |
IL (1) | IL87621A0 (en) |
NO (1) | NO883896L (en) |
NZ (1) | NZ226005A (en) |
PH (1) | PH26813A (en) |
PT (1) | PT88385B (en) |
ZA (1) | ZA886471B (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3818055A1 (en) * | 1988-05-27 | 1989-11-30 | Biotest Pharma Gmbh | COMBINATION OF HUMAN IMMUNOGLOBULINS AND INTERLEUKIN-2 FOR THE TREATMENT OF INFECTION DISEASES |
GB8820378D0 (en) * | 1988-08-26 | 1988-09-28 | Offord R E | Chemical compounds |
GB8820377D0 (en) * | 1988-08-26 | 1988-09-28 | Offord R E | Chemical compounds |
KR900005995A (en) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
DE3839332A1 (en) * | 1988-11-22 | 1990-05-23 | Bayer Ag | METHOD FOR PRODUCING SUBSTITUTED 2-CHLORINE PYRIDINES |
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5478804A (en) * | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
DK0565620T3 (en) * | 1991-01-03 | 1996-01-22 | Salk Inst For Biological Studi | Mitotoxin for the treatment of vascular damage |
JPH06506667A (en) * | 1991-02-04 | 1994-07-28 | ユニバーシティ オブ サスカチェワン | Drug delivery of encapsulated VP6 |
PT100090A (en) * | 1991-02-04 | 1993-07-30 | Univ Saskatchewan | Method for targeting and release of drugs |
JP3105629B2 (en) * | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | Cell activity regulating conjugates of members of specific binding pairs |
EP0533006A1 (en) * | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
US7754211B2 (en) | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
ES2210514T3 (en) * | 1996-04-10 | 2004-07-01 | Sangstat Medical Corporation | SPECIFIC UNION COUPLE MEMBER CYCLING CONJUGATES |
IT1289608B1 (en) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL |
EP1037927B1 (en) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
DK1200479T3 (en) | 1999-08-09 | 2006-05-15 | Emd Lexigen Res Ct Corp | Multiple cytokine-antibody complexes |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
US7033594B2 (en) | 2000-03-31 | 2006-04-25 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
BR0209177A (en) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Recombinant tumor specific antibody and use |
IL159894A0 (en) | 2001-07-17 | 2004-06-20 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins |
EP2354791A1 (en) | 2001-12-04 | 2011-08-10 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
BRPI0317376B8 (en) | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | antibody-il2 fusion protein designated as hu14.18-il2, uses thereof, vector and pharmaceutical composition |
RU2369616C2 (en) | 2003-12-30 | 2009-10-10 | Мерк Патент Гмбх | Fused proteins il-7 |
WO2005070967A2 (en) | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CN101351477B (en) | 2005-12-30 | 2011-11-16 | 默克专利有限公司 | Anti-CD19 antibodies with reduced immunogenicity |
PL1966238T3 (en) | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
MX2011011044A (en) | 2009-04-22 | 2011-11-04 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites. |
JP5879713B2 (en) * | 2010-12-09 | 2016-03-08 | ソニー株式会社 | Image processing apparatus, image processing method, and program |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
DK2986312T3 (en) | 2013-04-19 | 2022-02-14 | Cytune Pharma | CYTOKINE DERIVATIVE TREATMENT WITH REDUCED VASCULAR MEDICAL SYNDROME |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1564666A (en) * | 1978-05-31 | 1980-04-10 | Ng Mun Hon | Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof |
-
1988
- 1988-08-30 EP EP88114130A patent/EP0305967B1/en not_active Expired - Lifetime
- 1988-08-30 AT AT88114130T patent/ATE88900T1/en not_active IP Right Cessation
- 1988-08-30 PH PH37474A patent/PH26813A/en unknown
- 1988-08-30 DE DE8888114130T patent/DE3880766D1/en not_active Expired - Fee Related
- 1988-08-30 ES ES88114130T patent/ES2054753T3/en not_active Expired - Lifetime
- 1988-08-31 NZ NZ226005A patent/NZ226005A/en unknown
- 1988-08-31 ZA ZA886471A patent/ZA886471B/en unknown
- 1988-08-31 FI FI884013A patent/FI884013A/en not_active IP Right Cessation
- 1988-08-31 PT PT88385A patent/PT88385B/en not_active IP Right Cessation
- 1988-08-31 IL IL87621A patent/IL87621A0/en unknown
- 1988-09-01 AU AU21725/88A patent/AU627694B2/en not_active Ceased
- 1988-09-01 JP JP63216441A patent/JPS6490200A/en active Pending
- 1988-09-01 NO NO88883896A patent/NO883896L/en unknown
- 1988-09-01 KR KR1019880011274A patent/KR890005137A/en not_active Application Discontinuation
- 1988-09-01 DK DK486588A patent/DK486588A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI884013A0 (en) | 1988-08-31 |
FI884013A (en) | 1989-03-03 |
IL87621A0 (en) | 1989-01-31 |
ZA886471B (en) | 1989-04-26 |
PH26813A (en) | 1992-11-05 |
DK486588A (en) | 1989-03-03 |
ATE88900T1 (en) | 1993-05-15 |
EP0305967A3 (en) | 1990-01-31 |
AU2172588A (en) | 1989-03-23 |
EP0305967B1 (en) | 1993-05-05 |
NO883896L (en) | 1989-03-03 |
DK486588D0 (en) | 1988-09-01 |
KR890005137A (en) | 1989-05-13 |
DE3880766D1 (en) | 1993-06-09 |
NO883896D0 (en) | 1988-09-01 |
JPS6490200A (en) | 1989-04-06 |
EP0305967A2 (en) | 1989-03-08 |
AU627694B2 (en) | 1992-09-03 |
ES2054753T3 (en) | 1994-08-16 |
PT88385B (en) | 1992-10-30 |
PT88385A (en) | 1989-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ226005A (en) | Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof | |
MX9302160A (en) | PHARMACEUTICAL COMPOSITIONS OF THE CONCORDING HUMAN COCIT LEU INTERFERON. | |
AU586860B2 (en) | Therapeutical application of phosphonylmethoxyalkyl adenines | |
ATE358176T1 (en) | HUMAN DNASE | |
FI862011A (en) | THERAPEUTIC NUCLEOSIDER. | |
DE3776946D1 (en) | NASAL ADMINISTRATION OF MEDICINAL PRODUCTS. | |
DK602988A (en) | NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL EFFECT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS | |
DE59101397D1 (en) | O-GLYCOSYLATED IFN ALPHA. | |
EP0296573A3 (en) | Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions | |
DK0500773T3 (en) | Non-glycosylated FGF-4 and preparations containing this | |
NO931413D0 (en) | METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES | |
IL89248A0 (en) | Antiviral synergistic pharmaceutical combination preparations | |
DE3773295D1 (en) | HOMOGENEOUS RECOMBINANT IMMUNE INTERFERON FRAGMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
ES2037807T3 (en) | MEDICINES CONTAINING IN INTERFERON COMBINATION AND 1-DEOXY-PIPERIDINES, PROCEDURE FOR THEIR MANUFACTURE AND APPLICATION. | |
MY111746A (en) | Therapeutic nucleosides. | |
DK0572557T3 (en) | Use of topotecan in the manufacture of a medicament for use in the treatment of ovarian cancer | |
DK0427633T3 (en) | Use of a polypeptide with gamma interferon activity for the preparation of pharmaceutical preparations intended for the treatment of primitive pleural cancer |